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Pleomorphic xanthoastrocytoma (PXA) is a rare brain tumor. Anaplastic features are found 
in 20–30% of cases of PXA and are associated with poor outcomes. Typical treatment is with 
gross total resection, followed by radiation therapy and cytotoxic chemotherapy at relapse. 
BRAFV600 mutations have been identified in 38–60% of patients with PXA. Several case 
reports and small case series have identified clinical benefit with BRAF inhibition in patients 
with BRAFV600-mutated PXA. We report the second published case of successful treatment 
with the BRAF inhibitor dabrafenib in a female patient with relapsed anaplastic PXA with 
a BRAFV600 mutation, and the first published case of dabrafinib treatment following 
intolerance to vemurafenib.
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Background
●● pleomorphic xanthoastrocytoma
Pleomorphic xanthoastrocytoma (PXA) is a rare brain tumor, with an incidence of fewer than 0.07 
cases per 100,000. It most commonly affects children and young adults, with a median age of diag-
nosis of 20.5–30.5 years. There is no significant gender difference [1–4]. A total of 97–99% of tumors 
are supratentorial, most frequently occurring in the temporal lobe. The most common initial symp-
tom is seizures, occurring in 64–75% at presentation [1–3]. Other frequent clinical features include 
focal  neurological deficits, visual disturbance, raised intracranial pressure and rarely, intracerebral 
hemorrhage [5].
PXA have a typical MRI appearance of a cystic mass with a prominent solid component that 
is isointense to gray matter on T1-weighted views, mildly hyperintense in T2-weighted views, 
practice points
 ●  Pleomorphic xanthoastrocytoma (PXA) is an uncommon brain tumor.
 ●  Anaplastic PXA (20–30%) has recently been reclassified as a WHO grade III tumor (previously grade II).
 ●  Typical treatment is with gross total resection, radiotherapy and cytotoxic chemotherapy.
 ●  BRAFV600 mutation status should be determined for all patients with PXA.
 ●  BRAF inhibitors such as dabrafenib and vemurafenib may be effective in the treatment of BRAFV600-mutated PXA.
 ●  Due to well-recognized acquired resistance mechanisms, combining BRAF and MEK inhibitors may be more effective.
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enhancing with gadolinium and with variable 
surrounding edema [6]. Purely solid and cystic 
forms also exist. PXAs are histologically distinct 
with pleomorphic giant cells with  xanthomatous 
change, presence of eosinophilic granular bodies 
and dense deposition of intracellular reticulin [7].
Anaplastic features are found in 20–30% of 
cases and include a high mitotic index (≥5/10 high-
powered fields) with or without necrosis [2,3]. 
Anaplasia confers a poorer progression-free and 
overall survival, although less reliably than in 
astrocytomas [7]. This aggressive variant of PXA 
has been recognized as a separate clinical entity in 
the recently published 2016 WHO Classification 
of Tumors of the CNS, termed ‘anaplastic PXA’, 
and now classed as a grade III tumor, having pre-
viously been categorized as a grade II tumor in the 
2007 edition [8,9].
Typical treatment is gross total resection if 
feasible, followed by radiotherapy and cytotoxic 
chemotherapy at recurrence. Five-year overall 
survival is 76–80% in all patients with PXA, 
and 57% in those with anaplasia [1,3].
●● BRaFV600 mutations
A seminal study investigating the MAPK signal-
transduction pathway identified mutations in 
BRAF as a key driver of oncogenesis in a number 
of human cancers, most notably melanoma [10]. 
More than 95% of BRAF mutations are a sub-
stitution of valine by glutamate at amino acid 
position 600 (BRAF V600) that initiates consti-
tutive and proneoplastic activation of the MAPK 
pathway [10,11]. The BRAFV600 mutation is 
found in 38–60% of patients with PXA [1,12–15]. 
It is unclear whether a BRAF mutation alone 
affects prognosis [1]. In glioma mouse models, 
BRAF mutation alone is insufficient to initi-
ate tumorgenesis. However, the combination of 
cyclin-dependent kinase inhibitor 2A loss with 
mutated BRAF generates malignant transforma-
tion [16]. Concomitant cyclin-dependent kinase 
inhibitor 2A deletion and BRAF mutation have 
been frequently identified in PXA [11].
●● BRaF inhibition
The introduction of drugs that inhibit mutant 
BRAF has dramatically changed the clinical out-
comes of patients with BRAF-mutated tumors. 
The most robust data of efficacy are from 
large clinical trials in patients with  metastatic 
melanoma.
A pivotal Phase III randomized trial com-
pared the BRAF inhibitor vemurafenib with 
dacarbazine (standard therapy) in 675 patients 
with BRAFV600-mutated metastatic mela-
noma [17]. There were superior response rates 
(48 vs 5%), progression-free survival (5.3 vs 
1.6 months [HR: 0.26 95% CI: 0.2–0.33, 
p < 0.001]) and 6-month survival (84% 
[95% CI: 78–89%] vs 64% [56–73]) in the 
vemurafenib arm. A further large Phase III 
random ized trial compared the BRAF inhibi-
tor dabrafenib with dacarbazine in 250 patients 
with previously untreated BRAFV600 mutant 
metastatic melanoma with improved response 
rates (50% [42.4–57.1] vs 6% [1.8–15.5]) and 
progression-free survival (5.1 vs 2.7 months [HR: 
0.3, 95% CI: 0.18–0.51, p < 0.001]) in the dab-
rafenib arm [18]. The most frequent side-effects 
of BRAF inhibitor therapy were arthralgia, rash, 
fatigue, cutaneous squamous cell carcinoma and 
keratoacanthoma. Comparing the two trials, 
dabrafenib appeared to be better tolerated than 
vemurafenib, with a lower incidence of skin tox-
icity. Treatment of melanoma patients with brain 
metastases demonstrated the efficacy of BRAF 
inhibitors in the CNS, with similar responses in 
intracranial and extracranial disease [13].
There is some evidence for the use of BRAF 
inhibitors in BRAFV600 mutant PXA. A Phase 
II ‘basket’ study of vemurafenib in 122 patients 
with nonmelanoma cancers with BRAFV600 
mutations included four patients with PXA [19]. 
Of these, 3/4 patients had a partial response 
and 1/4 patient had a best response of stable 
disease. In a case series of four patients with 
PXA (one with anaplasia) with BRAFV600 
mutations treated with salvage vemurafenib, 
best response assessments were partial response 
in one patient, stable disease in two patients 
and progressive disease in one patient [20]. The 
median overall survival was 8 months (range: 
4–14 months), and median progression-free 
survival was 5 months (range: 2–10 months). 
All patients previously had surgical resection, 
radiotherapy and chemotherapy (PCV or temo-
zolomide). Three case reports describe treatment 
with vemurafenib in three separate patients with 
anaplastic PXA [21–23]. All of these patients had 
been previously treated with surgical debulk-
ing, radiotherapy and chemotherapy. Two cases 
report tumor regression on MRI (1 near com-
plete response) and the third case reported sta-
ble disease on follow-up imaging. The reported 
toxicities are consistent with those character-
ized in clinical trials in patients with melanoma 
described above.
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Figure 1. MRI performed at initial presentation. (a) Axial T1 sequence with Gadolinium. (B) Axial T2 
sequence.
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There is a single published case report of 
dabrafenib use in PXA. A patient with pri-
mary meningeal PXA with anaplastic features 
was commenced on dabrafenib following sur-
gery and radiation, with subsequent significant 
improvement in tumor-related symptoms and 
reduction in disease on imaging [24]. The patient 
developed progressive disease 3.5 months later 
(although therapy was withheld for several weeks 
due to an intracranial hemorrhage) and died a 
few weeks later.
Case
A 21-year-old university student initially pre-
sented in June 2014 with a 1 month history of 
crescendo headache, vomiting, blurred vision 
and somnolence. MRI of the brain demon-
strated a large mass with a pleomorphic appear-
ance within the right middle cranial fossa. There 
was a large enhancing soft tissue nodule at the 
medial inferior aspect, a large cystic component 
and surrounding vasogenic edema with midline 
shift (Figure 1).
The patient had an emergency drainage of 
the large temporal cyst with initial histology 
reported as glioblastoma. Eleven days later 
she underwent a right temporal craniotomy 
and gross total resection. Final histology was 
reported as PXA with anaplastic features, and 
a BRAFV600 mutation was identified. Her 
symptoms resolved. The patient received adju-
vant RapidArc intensity modulated radiotherapy 
(54.9 Gray in 33 fractions), completed in August 
2014. In September and October 2014 she had 
several stereotypical episodes which “felt like 
being washed over with hot and cold water”, 
with a “feeling” in her abdomen. These were 
diagnosed as temporal lobe seizures and she was 
commenced on lamotrigine.
An MRI scan in November 2014 (Figure 2) 
identified an increase in the volume of enhanc-
ing tissue in the surgical bed, suspicious for 
disease progression. The patient had a second 
right temporal craniotomy and complete resec-
tion. Histology was consistent with tumor recur-
rence. She was subsequently commenced on 
vemurafenib 960 mg twice daily in December 
2014. Eleven days later she developed a wide-
spread macular rash throughout her trunk and 
limbs. She stopped vemurafenib, commenced 
hydrocortisone cream and her rash subsequently 
resolved. Vemurafenib was recommenced at a 
25% dose reduction 17 days later. The follow-
ing day she developed a similar widespread rash. 
Vemurafenib was stopped and the rash again 
resolved. An MRI in February 2015 showed 
slight thickening in enhancement in the floor 
of the right middle cranial fossa. At this point 
10.2217/cns-2016-0031
Figure 2. axial MRI with gadolinium. (a) Enhancing tissue within surgical bed, suspicious for tumor 
recurrence. (B) No evidence of recurrence after resection and 18 months of BRAF inhibitor therapy.
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she was commenced on dabrafenib 150 mg twice 
daily which she continues to take. In her last 
review in June 2016 she was well, with mild 
fatigue, but no other toxicities of dabrafenib or 
symptoms of her tumor. Serial MRI has shown 
no recurrence of her PXA.
Discussion
Our case is the second report of dabrafenib treat-
ment in PXA, the first of successful treatment 
in PXA with dabrafenib following intolerance 
to vemurafenib and adds to the growing litera-
ture on the successful use of BRAF inhibitors in 
patients with PXA.
In clinical trials of BRAF inhibitors in meta-
static melanoma while initial response rates 
are impressive, acquired resistance to BRAF 
inhibitors occurs in a significant proportion 
of patients. One of the most frequent causes of 
acquired resistance is reactivation of the MAPK 
pathway [25,26]. Furthermore,  paradoxical acti-
vation of the MAPK pathway in cells with-
out BRAF mutations has been implicated in 
the development of secondary skin tumors in 
patients treated with BRAF inhibitors [27,28]. 
MEK is an essential component of the MAPK 
pathway [29]. Trametinib, a MEK inhibitor, in 
combination with dabrafenib was superior to 
BRAF inhibition alone in two Phase III clini-
cal trials in metastatic melanoma, with similar 
toxicity profiles [30,31]. Combination BRAF and 
MEK inhibition is now the standard treatment 
in BRAFV600 mutant metastatic melanoma [32].
Conclusion
In conclusion, all patients with PXA should be 
tested for the BRAFV600 mutation. If present 
we advocate that they should be commenced on 
combination BRAF and MEK inhibition with 
dabrafenib and trametinib.
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